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Abstract
Serdemetan (JNJ-26854165), an antagonist to Mdm2, was anticipated to promote the activation of p53. While regulation of
p53 by Mdm2 is important, Mdm2 also regulates numerous proteins involved in diverse cellular functions. We investigated if
Serdemetan would alter the Mdm2-HIF1a axis and affect cell survival in human glioblastoma cells independently of p53.
Treatment of cells with Serdemetan under hypoxia resulted in a decrease in HIF1a levels. HIF1a downstream targets, VEGF
and the glycolytic enzymes (enolase, phosphoglycerate kinase1/2, and glucose transporter 1), were all decreased in
response to Serdemetan. The involvement of Mdm2 in regulating gene expression of glycolytic enzymes raises the
possibility of side effects associated with therapeutically targeting Mdm2.
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Introduction
Mdm2 is part of an ubiquitin ligase complex and is commonly
known to target p53 tumor suppressor protein for ubiquitination.
p53 is frequently lost or mutated in human cancers, while Mdm2 is
found to be highly overexpressed in multiple types of cancer.
These alterations in Mdm2 and p53 levels contribute to the
refractory nature of cancer cells to initiate apoptosis. While the
pathways whereby Mdm2 can provide resistance to apoptosis are
not well understood, one possible mechanism is the complex
formation of Mdm2 and Hypoxia inducible factor 1a (HIF1a), a
transcription factor activated in response to hypoxic stimuli.
HIF1a promotes angiogenesis and upregulates metabolic genes,
which are necessary to sustain tumor cells [1,2]. Complex
formation with Mdm2 is important for HIF1a stabilization and
the induction of vascular endothelial growth factor (VEGF) [3–5].
Serdemetan (JNJ-26854165) is a novel small molecule identified
by Johnson & Johnson Pharmaceutical R&D as an antagonist to
Mdm2. Serdemetan, a tryptamine derivative, can synergize with
DNA damaging compounds and elicit a p53 apoptotic response in
leukemia cells [6]. In solid tumor cell lines, Serdemetan was
observed to enhance radiosensitization and delayed tumor growth
by inhibiting proliferation and also blocking the migration of
endothelial cells [7]. Recruitment of these endothelial cells by the
secretion of factors such as VEGF is necessary for angiogenesis.
Angiogenesis and glycolysis are essential for tumor cell survival.
In this study, we examined the affects of hypoxia and
Serdemetan on human glioblastoma cell lines that have functional
(U87 and SF767) and non-functional p53 (U373). We found that
Serdemetan altered the ability of Mdm2 to stabilize HIF1a, which
resulted in a decrease in VEGF and other HIF1a targets involved
in glycolysis. The decrease in HIF1a levels and downstream
targets was evident in glioblastoma cells regardless of p53 status.
Moreover, our data provide a novel mechanism whereby the
Mdm2-HIF1a axis is responsible for inducing glycolytic genes.
Additionally, the survival of all three glioblastoma cell lines was
diminished with Serdemetan under hypoxia, implicating a role for
Mdm2 in regulating pathways aside from the ascribed function in
ablating p53 activity.
Materials and Methods
Materials
A working stock concentration of 10 mM JNJ-26854165
(Johnson & Johnson) (Serdemetan) was subsequently diluted to
the concentrations given. The antibodies used for detection were:
enolase (5A4), GAPDH (6C5), Glut1 (H-43), HIF1a (HIa-67),
Mdm2 (SMP14), p21 (C-19), p53 (DO-1), PGK1/2 (A-5), a-
tubulin (TU-02), and VEGF (147) from Santa Cruz Biotech.
Mdm2 (2A10), Mdm2 (4B11) were obtained from EMD.
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Cell Culture
The human glioblastoma cell lines U87MG, SF767, and U373
(ATCC) were cultured at 37uC in a humidified incubator with 5%
CO2. All cell lines were maintained in Dulbecco’s modified Eagle’s
medium with high glucose (Invitrogen) supplemented with 10%
fetal bovine serum and 50 units/mL of penicillin and 50 mg/mL
of streptomycin sulfate (Invitrogen). Survival assays were complet-
ed by plating 12 well plates with 150,000 cells per well with
Serdemetan or DMSO in hypoxia for 48 h. Cells were stained
with methylene blue and the dye was liberated using 0.5 mol/L
HCl for quantitation by measuring absorbance at 595 nm.
Western Blotting and Cytoplasmic/nuclear Fractionation
Cells for whole cell lysates were solubilized in lysis buffer:
25 mM Tris HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% IGEPAL, 1 mM phenylmethylsulfonyl fluoride
(PMSF), 10 mg/mL aprotinin, 10 mg/mL leupeptin, 1 mM
sodium orthovanadate (Na3VO4) and 10 mM sodium fluoride
(NaF). Lysates were boiled in 1X Laemmli buffer prior to Western
blotting analysis. Nuclear and cytoplasmic extracts were made as
previously described [8].
Reporter Assay
Reporter assay methods have been previously described [4].
Results
The p53-Mdm2 interaction was first successfully targeted for
pharmacological inhibition using the Nutlin3 compound. Other
compounds have been developed to target Mdm2 including
Serdemetan (JNJ-26854165). Since Nutlin3 elevates p53 levels
through inhibition of Mdm2–p53 binding, we tested whether
Serdemetan has a similar mechanism of action. Although
Serdemetan led to a dose dependent increase in p53 levels in
U87MG cells which plateaued at 30 mM, it did not lead to a
robust induction of Mdm2 as seen with Nutlin3. (Fig. 1A). We next
examined the effect of Serdemetan on the induction of p21, a
downstream target gene of p53, in cells that maintain wild type
p53 (U87MG and SF767) or gain of function mutant p53 (U373).
Despite the elevated p53 levels, there were no changes in p21
levels (Fig. 1B). These data suggest that p53 is not transcriptionally
active with Serdemetan alone, contrary to the reported functions
of nutlin3 that cause the induction of p21 [9].
We and others have previously reported that Mdm2 can
increase the stability of hypoxia inducible factor 1 alpha (HIF1a)
[4,5]. HIF1a levels and the induction of the downstream target
genes, VEGF and EPO, were dramatically decreased when Mdm2
was absent or cells were treated with Nutlin3 [4,10]. To examine if
Serdemetan functions similarly to Nutlin3 on the Mdm2 -HIF1a
interplay (4), we analyzed HIF1a levels in the presence of
Serdemetan under normoxic and hypoxic conditions. Our data
show that HIF1a levels were increased with hypoxia as expected,
yet this elevation was not evident in the presence of Serdemetan
(Fig. 2A). Upon further examination of nuclear and cytoplasmic
extracts from U87 cells treated with Serdemetan, we found that
the levels of HIF1a in the nuclear fraction were negligible
compared to the DMSO control (Fig. 2B). To determine if the
effects of Serdemetan on HIF1a were dependent on the
proteasome, pre-treatment with the proteasome inhibitor,
MG132, and Serdemetan under hypoxic conditions resulted in
detectible levels of HIF1a in the nuclear fraction (Fig. 2C).
Together, these results demonstrate that Serdemetan inhibits the
stabilizing actions of Mdm2 on HIF1a in hypoxic conditions.
HIF1a is a transcriptional factor for many genes including vegf
and several genes involved in glycolysis. VEGF is a critical
component and necessary for re-direction of blood flow and
nutrients to tumor sites under hypoxic conditions. Since treatment
of Serdemetan resulted in low levels of nuclear HIF1a (Wic. 2B),
we examined vegf promoter activity by luciferase reporter assay in
U87 cells, and VEGF levels by western blot in U373 and SF767
cells. VEGF levels as measured by luciferase, real time PCR, and
western blot were diminished in the presence of Serdemetan
(Fig. 3A,and B).
We next examined if the expression of a select number of
HIF1a glycolytic-targets were altered by Serdemetan in U87,
SF767, and U373 cells under hypoxic conditions. Enolase, Glut1,
MMP2 and PGK1/2 were decreased with Serdemetan treatment
compared to DMSO controls (Fig. 3C). Considering that most
cancer cells are addicted to glycolysis to generate energy for
survival, we examined if Serdemetan would affect cell survival
incubated under hypoxic conditions. We observed that treatment
with Serdemetan and hypoxia resulted in a fewer number of viable
cells by 48 h in a colony-forming assay (Fig. 4). This effect was
independent of the p53 status as all cell lines tested were sensitive
to Serdemetan.
Discussion
Glioblastoma multiforme is characterized as a high-grade
multicellular glioma subtype that represents one of the most
aggressive forms of cancer with poor clinical prognosis and
outcome [11]. Since human malignant glioblastoma are refractory
to conventional therapeutic approaches, we examined if Serde-
metan had an effect in human glioblastoma cell lines. Serdemetan
has been reported to increase p53 protein levels in multiple cancer
cell lines and mice [6,7,12]. In agreement with other studies using
different cell lines, we found elevated p53 levels in U87
glioblastoma cells after Serdemetan exposure (Fig. 1A and B).
While Serdemetan treatment has resulted in an increase in some
p53 targets, this was not consistent in every cell line examined.
Thus, it seems that this compound is not a strong activator of p53,
which is evident in our study. Indeed, we observed that treatment
of Serdemetan was not effective at inducing p21 in glioblastoma
cells that maintain wild type p53 or gain of function mutant p53
(Fig. 1). We did observe that Serdemetan treatment modestly
elevated Mdm2 protein levels, which did not depend on p53.
These data suggest that engagement of p53 transcriptional activity
is not the primary mechanism whereby Serdemetan may function
(Fig. 1).
Rapid proliferation of tumor cells away from the vasculature
results in a microenvironment of limited oxygen (1% oxygen or
less). In this hypoxic environment, the transcription factor HIF1a
is elevated, which induces vegf gene expression, a growth factor
necessary for stimulating angiogenesis and permeabilization of the
vessels. Detectable HIF1a protein is associated with tumor grade
and vascularization of glioblastoma patients whose survival is less
than a year [13]. Considering that solid tumor growth is under
hypoxic conditions, we examined the responsiveness of HIF1a
protein to Serdemetan exposure. We found that HIF1a and
VEGF levels were lower with Serdemetan treatment (Fig. 3A and
B). This observation supports the existence of an Mdm2-HIF1a-
VEGF axis. This data is also congruent with our previous report
showing that either loss of Mdm2 by genetic manipulation, or
using pharmacological blockade to prevent Mdm2-HIF1a bind-
ing, attenuated VEGF induction (4). A recent report has
demonstrated the importance of dual inhibition of Mdm2 and
VEGF in neuroblastomas, which subsequently led to slower tumor
Mdm2-HIF1a Regulates Glycolytic Enzymes
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growth and less vascularization of the tumors [14]. Serdemetan
does not appear to alter endothelial cells as measured by in vitro
neo-vessel formation in matrigel [7]. Collectively, Serdemetan is
effective at regulating the production of VEGF by the tumor cells
and not the action of VEGF on endothelial cells (Fig. 3).
It is necessary for tumor cells that have proliferated away from
vessels to utilize a non-mitochondrial energy source such as
glycolysis. Glycolytic genes are induced in response to limited
oxygen by HIF1a. Our data show that Serdemetan led to reduced
protein levels of multiple HIF1a stimulated gene targets (Fig. 3B).
Not surprisingly, we found that treatment with Serdemetan was
effective in decreasing cell survival of p53 wild type and p53
inactive cells (Fig. 4A and B). It was evident after 48 h that p53 cell
lines were more sensitive to Serdemetan, which may relate to the
fact that p53 could induce anti-metabolic pathways [15].
A recent Phase I clinical trial report of Serdemetan in patients
with advanced solid tumors determined that the maximum
tolerated dose of Serdemetan was 350 mg/once daily [12].
However, prolonged cardiac QT was associated with Serdemetan
treatment, which led to termination of the clinical trial. This
development was not surprising considering that cardiac QT can
be affected by glucose metabolism, and Serdemetan treatment
decreases at least several enzymes in the glycolytic pathway (Fig. 3).
In summary, our current studies highlight the molecular pitfalls of
using Serdemetan or other Mdm2 targeting compounds in solid
tumor treatment. The fundamental Mdm2-HIF1a axis that is
Figure 1. The effect of Serdemetan on p53 levels. A) Chemical structure of Serdemetan (SE) and Nutlin3. Western blot of U87 cell lysates
treated with increasing concentrations of Nutlin3 or Serdemetan for 6 h to detect p53, Mdm2 and GAPDH. B) Western blot of p53, p21 and GAPDH
from U373, SF767, and U87. Whole cell lysates were prepared from cells treated with either DMSO or 10 mM Serdemetan (SE) for 6 h.
doi:10.1371/journal.pone.0074741.g001
Figure 2. Detection of HIF1a in response to Serdemetan
treatment. A) Western blot of HIF1a, Mdm2 and GAPDH from
SF767, U87 and U373 cellular extracts. Cells were subjected to
treatment of either 21% oxygen or hypoxic (1%) conditions for 6 h
with 10 mM Serdemetan (Se) or DMSO (C). B) Western blot analysis of
HIF1a, tubulin, and PARP from cytoplasmic (C) and nuclear (N) extracts
of SF767 cells treated with 10 mM of Serdemetan (Serd) or DMSO
(Control). C) Western blotting was performed for HIF1a, tubulin, and
PARP as described above with the addition of pretreatment with 10 mM
MG132 for 16 h.
doi:10.1371/journal.pone.0074741.g002
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Figure 3. Analysis of HIF1a targets in response to Serdemetan. A) Luciferase assay of U87 cells transfected with the 4X HRE luciferase
construct (left panel) or real time PCR for vegf from U87 cells (right panel) treated with 10 mM Serdemetan or DMSO under hypoxic conditions. B)
Western blot of VEGF levels in SF767 and U373 cells. Cells were treated with 10 mM Serdemetan or DMSO control under hypoxic conditions. C)
Western blot analysis of enolase, Glut1, PGK1/2 and GAPDH from U87 and U373 cells. Cells were treated with 30 mM of Serdemetan and subjected to
hypoxia for 24 h.
doi:10.1371/journal.pone.0074741.g003
Figure 4. Survival of cells treated with Serdemetan. A) Colony forming assay was performed on SF767, U373, and U87 cells under hypoxia for
48 h with DMSO or Serdemetan. B) Quantitation of the colony-forming assay by measuring the absorbance at 595 nm as percent change from
DMSO. Error bars represent standard deviation as calculated from the mean (n = 3).
doi:10.1371/journal.pone.0074741.g004
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necessary to regulate downstream glycolytic enzymes is pivotal for
normal physiological metabolism. Overall, Mdm2 governs many
pathways independently of p53 and these pathways must be
considered to alleviate detrimental long-term side affects in
patients.
Acknowledgments
Johnson and Johnson for providing Serdemetan.
Author Contributions
Conceived and designed the experiments: LDM. Performed the experi-
ments: JAL PMH JMG JAE CNB LDM. Analyzed the data: MPK AA
LDM. Contributed reagents/materials/analysis tools: LDM AA MPK.
Wrote the paper: JAL PMH JMG MPK LDM.
References
1. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, et al. (2000)
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-
inducible factor 1alpha. Genes Dev 14: 34–44.
2. Dang CV, Semenza GL (1999) Oncogenic alterations of metabolism. Trends
Biochem Sci 24: 68–72.
3. Nieminen AL, Qanungo S, Schneider EA, Jiang BH, Agani FH (2005) Mdm2
and HIF-1alpha interaction in tumor cells during hypoxia. J Cell Physiol 204:
364–369.
4. LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, et al. (2007)
Nutlin3 blocks vascular endothelial growth factor induction by preventing the
interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Res 67:
450–454.
5. Bardos JI, Chau NM, Ashcroft M (2004) Growth factor-mediated induction of
HDM2 positively regulates hypoxia-inducible factor 1alpha expression. Mol Cell
Biol 24: 2905–2914.
6. Kojima K, Burks JK, Arts J, Andreeff M (2010) The novel tryptamine derivative
JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute
myeloid and lymphoid leukemias. Mol Cancer Ther 9: 2545–2557.
7. Chargari C, Leteur C, Angevin E, Bashir T, Schoentjes B, et al. (2011)
Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine
compound with radiosensitizing activity in vitro and in tumor xenografts.
Cancer Lett 312: 209–218.
8. Lehman JA, Waning DL, Batuello CN, Cipriano R, Kadakia MP, et al. (2011)
Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-
PTEN) protein complex in response to genotoxic stress. J Biol Chem 286:
36631–36640.
9. Cao C, Shinohara ET, Subhawong TK, Geng L, Kim KW, et al. (2006)
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double
minute 2. Mol Cancer Ther 5: 411–417.
10. Lee YM, Lim JH, Chun YS, Moon HE, Lee MK, et al. (2009) Nutlin-3, an
Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-
mediated inactivation of HIF-1alpha. Carcinogenesis 30: 1768–1775.
11. Lim SK, Llaguno SR, McKay RM, Parada LF (2011) Glioblastoma multiforme:
a perspective on recent findings in human cancer and mouse models. BMB Rep
44: 158–164.
12. Tabernero J, Dirix L, Schoffski P, Cervantes A, Lopez-Martin JA, et al. (2011) A
phase I first-in-human pharmacokinetic and pharmacodynamic study of
serdemetan in patients with advanced solid tumors. Clin Cancer Res 17:
6313–6321.
13. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, et al. (2000)
Expression of hypoxia-inducible factor 1alpha in brain tumors: association with
angiogenesis, invasion, and progression. Cancer 88: 2606–2618.
14. Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, et al. (2011) Effect
of MDM2 and vascular endothelial growth factor inhibition on tumor
angiogenesis and metastasis in neuroblastoma. Angiogenesis 14: 255–266.
15. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, et al. (2006) TIGAR, a
p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107–120.
Mdm2-HIF1a Regulates Glycolytic Enzymes
PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e74741
